Cervix Cancer Clinical Trial
Official title:
A Novel Functional Imaging Technique With FLT-PET/MRI For Staging, Response Assessment and Radiation Treatment Planning in Cervix Cancer
This pilot study aims to monitor early tumour response based on [18F]FLT-PET/MRI scans and to determine the feasibility of personalised radiotherapy to spare active bone marrow areas identified by [18F]FLT-PET/MRI. Bone marrow within the pelvis will be outlined by employing 18FLT PET to identify active BM within bony structures. Subsequently, treatment plans with various conformal radiotherapy techniques will be generated with different optimization approaches toward bone marrow while ensuring adequate tumor coverage. Dosimetric comparison amongst plans will be carried out.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 21 Years to 99 Years |
Eligibility | Inclusion Criteria: - Have given written informed consent, with the understanding that consent may be withdrawn at any time without prejudice - Histologically or cytologically confirmed cervical carcinoma - FIGO staged IB to IVA - Underwent MRI pelvis - Underwent FDG-PET/CT or MRI abdomen or CT thorax and abdomen or Chest X ray for routine staging - Planned for radical radiotherapy with or without chemotherapy - No distant metastasis in staging work up - ECOG 0-2 - Age 21 or over (no upper age limit) Exclusion Criteria: - Patients scheduled for neoadjuvant chemotherapy - Patients with previous hysterectomy or radiotherapy to the pelvis - Patients who are pregnant or lactating - Patients who do not meet the above mentioned inclusion criteria - Patients who refuse to give and/or sign the informed consent - Patients who currently have a pacemaker - Patients who have a history of serious adverse events related to a previous MRI or PET/CT - Patients who are unable to undergo MRI scanning - Patients with a known allergy against any component of the contrast enhancing agent - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule; these conditions should be discussed with the patient before registration in the trial. |
Country | Name | City | State |
---|---|---|---|
Singapore | National Cancer Centre Singapore | Singapore |
Lead Sponsor | Collaborator |
---|---|
National Cancer Centre, Singapore |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the feasibility of [18F]FLT-PET/MRI imaging for early prediction of treatment by comparison of changes in baseline SUV uptake at Week 4-5 of External Beam Radiotherapy | Baseline (1 to 28 days before prior initiation of radiotherapy) and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) | ||
Secondary | Compare SUV uptake of FLT with FDG PET at diagnosis | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) | ||
Secondary | Compare SUV uptake of FLT before and after chemoRT | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) | ||
Secondary | To compare differences in tumor and regional staging between PET/MRI, PET/CT and MRI scans, determined from the tumor size and extent of local involvement | Baseline (1 to 28 days before prior initiation of radiotherapy) and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) | ||
Secondary | Assess the feasibility of PET/MRI in the radiation treatment planning workflow with respect to the adequacy of image quality and image fusion of PET/MRI data with the treatment planning CT for marrow sparing RT plan | Through patient treatment completion, an average of 3 months | ||
Secondary | Compare changes in stimulated radiation treatment volume when derived from PET/MRI vs PET/CT vs MRI | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) | ||
Secondary | Compare VMAT versus IMRT versus proton versus tomotherapy for best marrow sparing plan | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) | ||
Secondary | To determine the correlation of [18F]FLT parameters as baseline, during treatment and change in [18F] FLT parameters with clinical outcome and response | Baseline, 1 to 28 days before prior initiation of radiotherapy and Week 4 - 5 of External Beam Radiotherapy (before brachytherapy) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04067882 -
Validation of the Genetic Signature 354849 as a Prognostic Method
|
||
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Recruiting |
NCT05743517 -
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
|
N/A | |
Completed |
NCT05234112 -
Prevention and Screening Towards Elimination of Cervical Cancer
|
N/A | |
Completed |
NCT04258553 -
Thiol Disulfide Balance in Cervix Cancer
|
||
Completed |
NCT03956498 -
Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy
|
N/A | |
Active, not recruiting |
NCT04357873 -
Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations
|
Phase 2 | |
Completed |
NCT00509444 -
Cancer Prevention and Treatment Among African American Older Adults: Treatment Trial
|
Phase 3 | |
Completed |
NCT00379743 -
Partnership for Healthy Seniors
|
N/A | |
Recruiting |
NCT06022029 -
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
|
Phase 1 | |
Recruiting |
NCT06116019 -
Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
|
||
Completed |
NCT04072913 -
Matrix Metalloproteinases and Human Papillomavirus in Dysplasias and Cancers of the Cervix
|
N/A | |
Active, not recruiting |
NCT06452004 -
Validation of Artificial Intelligence as Decision Support System in VIA (PRESCRIP-TEC)
|
N/A | |
Recruiting |
NCT04651127 -
Anti-PD-1 Antibody Combined With Histone Deacetylase Inhibitor in Patients With Advanced Cervical Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010875 -
A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT02552121 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02001623 -
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02997553 -
Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
|
Phase 3 | |
Terminated |
NCT02233387 -
PET CT With HX4 in Cervix Cancer
|
Phase 2 | |
Completed |
NCT01766284 -
Study of the Diagnostic Efficacy of "Real Time" Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix
|
N/A |